Lichen myxedematosus: a rare group of cutaneous mucinosis [PDF]
Anais Brasileiros de Dermatologia: Cutaneous mucinoses are a heterogeneous group of dermatoses in which excess deposition of mucin in the dermis gives the skin a waxy appearance, with papules and plaques that can vary from self-healing mucinosis to even disrupting the normal shape of a ...
Ramiro Eugenio Cárdenas-Gonzalez +2 more
doaj +2 more sources
Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report
BMC Pulmonary Medicine, 2020 Background Scleromyxedema is a progressive, systemic connective tissue disorder characterized by fibro-mucous skin lesions and increased serum monoclonal immunoglobulin levels.
Mazen Kreidy +3 more
doaj +1 more source
Scleromyxedema concurrent with dermatomyositis and paraproteinemia: A case report
Современная ревматология, 2015 The paper describes the case of a female patient who had at least three diseases: scleromyxedema, dermatomyositis/polymyositis (DM/PM), and paraproteinemia (monoclonal gammopathy).
M. N. Starovoitova +2 more
doaj +1 more source
Mechanism of NSF: New evidence challenging the prevailing theory [PDF]
, 2009 Nephrogenic systemic fibrosis (NSF) has been associated with the administration of gadolinium-based contrast agents in patients with severely impaired renal function (SIRF), endstage renal disease (ESRD), or acute renal failure (ARF).
Jimenez, MD, Sergio A. +1 more
core +2 more sources
Complications of nephrogenic systemic fibrosis following repeated exposure to gadolinium in a man with hypothyroidism: a case report [PDF]
, 2011 Introduction Nephrogenic systemic fibrosis is a condition that has recently been recognized in patients with chronic renal disease and is associated with use of gadolinium-based contrast agents of ubiquitous use in magnetic resonance imaging scans.
Aggarwal, Arpita +5 more
core +3 more sources
Clinical Case Reports, 2020 Scleromyxedema is a rare and progressive disease that currently has no standard treatment. Triplet therapy with lenalidomide, bortezomib, and dexamethasone can be an effective therapy for scleromyxedema, especially in patients with refractory or relapsed
Hninyee Win, Krisstina Gowin
doaj +1 more source
A Case of Multiple Myeloma Diagnosed by Skin Lesions [PDF]
, 2010 Multiple myeloma, being a malignant proliferation of plasma cells in the bone marrow, has clinical spectrum varying from monoclonal gammopathy with unknown significance to plasma cell leukemia.
Aylin Okçu Heper +3 more
core +1 more source
Clinical applications of immunoglobulin in neuromuscular diseases: focus on inflammatory myopathies [PDF]
, 2014 During recent years, an increasing number of neuromuscular diseases have been recognized either to be caused primarily by autoimmune mechanisms, or to have important autoimmune components.
Oliveira, Acary Souza Bulle +2 more
core +3 more sources
Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: A systematic review [PDF]
, 2012 Glatiramer acetate and interferon-beta are approved first-line disease-modifying treatments (DMTs) for multiple sclerosis (MS). DMTs can be associated with cutaneous adverse events, which may influence treatment adherence and patient quality of life.
Alava C +20 more
core +1 more source
Plasma cell myeloma masquerading as scleromyxedema
Indian Dermatology Online Journal, 2019 Scleromyxedema is a rare progressive cutaneous mucinosis of unknown etiology with equal prevalence in both men and women. It is usually associated with monoclonal gammopathy in most of the cases.
Varun Victor, Rashmi Maria Margareat
doaj +1 more source